Zoetis Inc. and Neogen Corporation announced on March 2 that the companies had entered into a definitive agreement for Zoetis to acquire Neogen’s global animal genomics business for $160 million.
The deal is subject to traditional closing conditions and pending satisfaction of regulatory requirements, but the companies expect the acquisition to be complete later this year. Zoetis has stated its desire for “a seamless integration, supporting continuity for colleagues and customers, and building on Neogen’s legacy of innovation in genomics.”
Neogen’s genomics business operates through laboratories in the U.S., Brazil, the UK, Australia and China to serve customers in more than 120 countries, utilizing an extensive genotyping platform and software solutions. It is best known in North America for its genomic solutions in the beef and dairy industries.
“Neogen’s genomics business has been a pioneer in advanced DNA testing for livestock and has set a high standard for innovation across the livestock sector, with globally recognized solutions spanning genomic prediction, herd improvement and data integration,” Tom Schultz, head of commercial global genomics at Neogen, said in a statement. “We’re excited to build on that foundation in our future with Zoetis and to continue advancing tools that strengthen animal health, performance and overall profitability. Customers can expect a thoughtful transition and continued excellent service.”
“The addition of Neogen’s genomics business strengthens our commitment to advancing animal health through innovation, data and technology,” Zoetis chief commercial officer Jamie Brannan said in a statement. “This acquisition brings complementary capabilities that expand predictive insights and individualized care, enabling us to deliver added value to customers.”
The announcement comes on the heels of Zoetis’s announcement in early February of new genetic predictions for bovine respiratory disease (BRD) health and survival for commercial and seedstock cow-calf producers through its Inherit Select platform, highlighting what the company hopes to be increased growth in its genomic prediction capabilities for livestock producers.
